Vesna Kramar
Senior Scientist Roche
Vesna Kramar is a Senior Scientist at Roche Oncology in Switzerland, with a decade of dedicated experience in the preclinical development of cancer immunotherapies. Throughout her tenure at Roche, she has been a key contributor to a diverse range of innovative projects, from the early-stage development of TCR-like antibodies targeting intracellular proteins to tumor-targeted costimulatory engagers. Her work has been instrumental in bridging the gap between discovery and the clinic, providing the essential data packages required for IND submissions and the design of clinical trial protocols. Today, she focuses on integrating multidisciplinary expertise to drive the strategy for next-generation oncology drugs and tailored future therapies.
Seminars
- Establishing the clinical PoM for two distinct costimulators, Englumafusp alfa (4-1BB) and CD28, in combination with Glofitamab for r/r NHL, showing how each engages a unique immunologic pathway
- Presents biomarker evidence (e.g., peripheral memory T‑cell expansion, ctDNA reduction) linking 4‑1BB to durable, late responses and CD28 to rapid, early tumor killing
- Identifies tumor microenvironment profiles where each costimulatory pathway performs optimally, supporting more personalized treatment selection for poor‑prognosis patients
